Press release
Comprehensive Biomarker Clinical Phase Outsourcing Services Market Insights: Forecasting Size, Growth, and Competitive Trends from 2025 to 2034
How Are the key drivers contributing to the expansion of the biomarker clinical phase outsourcing services market?The biomarker clinical phase outsourcing services market is predicted to grow due to the surge in clinical trials. These research studies, involving human subjects, are designed to determine the efficacy and safety measures of recent medical procedures, treatments, or diagnoses. The amplified volume of clinical trials owes to developments in the medical research sector, the growing incidence of chronic diseases, increased financing from both public and private sectors, and the escalating request for new-age treatments and therapies. Outsourcing providers typically possess specialized proficiency and experience in biomarker discovery, validation, and examination which can amplify the quality and dependability of the biomarker data procured during the trial. As an example, per the United States National Library of Medicine in May 2023, recorded clinical trials saw an increase from 399,499 in 2022 to 437,533 across 50 states and 221 countries. Moreover, the studies registered in the US alone totaled 140,492 (31%) while non-U.S. locations recorded 241,498 studies (53%). Hence, the escalating volume of clinical trials is anticipated to propel the biomarker clinical phase outsourcing services market's growth.
Get Your Biomarker Clinical Phase Outsourcing Services Market Report Here:
https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report
What growth opportunities are expected to drive the biomarker clinical phase outsourcing services market's CAGR through 2034?
In recent times, the biomarker clinical phase outsourcing services market has experienced significant expansion. The market size is projected to surge from $9.71 billion in 2024 to $11.94 billion in 2025, with a compound annual growth rate (CAGR) of 23.0%. Factors contributing to the growth in the historic period include heightened government initiatives and funding, an increase in the diagnostic applications of biomarkers, higher R&D funding from the government, swift progress in technologies like genomics, proteomics and imaging, along with growing demand for cancer biomarkers.
The biomarker clinical phase outsourcing services sector is projected to experience a sizeable expansion in the coming years, accelerating to a value of $27.09 billion by 2029 with a compound annual growth rate (CAGR) of 22.7%. The surge in the forecast period is the result of the growing application of biomarkers in various stages of clinical trials and an escalating demand for precision medicine, backed by a rise in the adoption of companion diagnostics and increasing demand for personalized medicine. The forecast period will also witness key trends including evolved principles in trials, a focus on diagnostic clinical phases, swift progress in biomarker technology, heightened government initiatives and funding, alongside technology advancements.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp
What are the emerging trends shaping the future of the biomarker clinical phase outsourcing services market?
Key players in the biomarker clinical phase outsourcing services industry, are concentrating on advancements in high-throughput flow cytometry and ELISpot testing to secure a competitive advantage in the market. These techniques serve as vital tools for biomarker analysis, enabling quick and accurate evaluation of immune responses and cellular markers. For example, in November 2022, Celerion Inc., a biotechnology outsourcing services company based in the US, broadened its array of services to incorporate GLP/GCP-compliant molecular and cell biology testing. This strategic initiative seeks to augment Celerion's capacity to assist clients throughout the drug development trajectory, from preliminary clinical research to regulatory filings. By incorporating GLP/GCP-compliant molecular and cell biology examinations, such as pharmacokinetic (PK), pharmacodynamic (PD), and biomarker analysis, Celerion is able to offer a wider range of services. This expansion allows Celerion to support their clients in the creation of high-standard data necessary to meet regulatory mandates, thus accelerating the creation of new drugs.
Which growth-oriented segments of the biomarker clinical phase outsourcing services market are leading the industry's development?
The biomarker clinical phase outsourcing services market covered in this report is segmented -
1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types
2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis
3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutions
Subsegments:
1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers
2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers
3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers
4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers
5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15740
What regions are leading the charge in the biomarker clinical phase outsourcing services market?
North America was the largest region in the biomarker clinical phase outsourcing services market in 2023. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What companies are at the forefront of innovation in the biomarker clinical phase outsourcing services market?
Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Intertek Group plc, Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Bioclinica Inc., Evotec SE, GenScript Biotech Corporation, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Selvita S.A., BioIVT LLC, Discovery Life Sciences LLC, Metabolon Inc., Caprion Proteomics Inc., Canopy Biosciences LLC
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=15740&type=smp
What Is Covered In The Biomarker Clinical Phase Outsourcing Services Global Market Report?
•Market Size Forecast: Examine the biomarker clinical phase outsourcing services market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the biomarker clinical phase outsourcing services market for a structured understanding.
•Key Players Overview: Analyze major players in the biomarker clinical phase outsourcing services market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the biomarker clinical phase outsourcing services market.
•Segment Contributions: Evaluate how different segments drive overall growth in the biomarker clinical phase outsourcing services market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the biomarker clinical phase outsourcing services market.
•Industry Challenges: Identify potential risks and obstacles affecting the biomarker clinical phase outsourcing services market.
•Competitive Landscape: Review strategic developments in the biomarker clinical phase outsourcing services market, including expansions, agreements, and new product launches.
Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Comprehensive Biomarker Clinical Phase Outsourcing Services Market Insights: Forecasting Size, Growth, and Competitive Trends from 2025 to 2034 here
News-ID: 3920339 • Views: …
More Releases from The Business Research Company

Eyewear Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Eyewear Market Size By 2025?
In recent years, the eyewear industry has experienced a robust growth. The market value is anticipated to increase from $158.53 billion in 2024 to $173.89 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 9.7%. Factors such…

Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Projected to Grow a …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Industry Market Size Be by 2025?
The oncology market, specifically in the realm of RNA-based oncolytic therapies, has experienced substantial growth in recent years; with its market size expected to rise from $1.78 billion in 2024 to $2.12 billion in 2025.…

Top Market Shifts Transforming the Interventional Oncology Devices Market Landsc …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Interventional Oncology Devices Market Through 2025?
The market for interventional oncology devices has experienced consistent growth in the past few years. The market size is expected to increase from $2.39 billion in 2024 to $2.5 billion in 2025, with a compound annual…

Global Rare Disease Pharmaceutical Service Industry Outlook 2025-2029: Market Se …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Rare Disease Pharmaceutical Service Market Size By 2025?
In recent times, the market size of rare disease pharmaceutical service has experienced significant growth. It is expected to escalate from $117.70 billion in 2024 to $133.40 billion in 2025, boasting a compound annual growth rate (CAGR)…
More Releases for Biomarker
Transformative Trends Impacting the Multiplex Biomarker Imaging Market Landscape …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Multiplex Biomarker Imaging Market Size By 2025?
In recent times, the size of the multiplex biomarker imaging market has experienced significant growth. There is an expected rise from $0.49 billion in 2024 to $0.54 billion in 2025, with a compound annual growth rate (CAGR) of…
Blood-Based Biomarker Market Beyond the Needle: The Future of Diagnostics Lies i …
Blood-Based Biomarker Market worth $51.71 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Blood-Based Biomarker Market - (By Type (Screening Biomarker, Diagnosis Biomarker, Others), By Disease (Cancer, Neurological Disorders, Others), By Application (Diagnostics, Drug Discovery, Personalized Medicine)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic,…
Biomarker Discovery Outsourcing Services Market Biomarker Discovery Outsourcing: …
Biomarker Discovery Outsourcing Services Market to reach over USD 52.82 billion by the year 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biomarker Discovery Outsourcing Services Market Size, Share & Trends Analysis Report By Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers And Surrogate Endpoints),
Therapeutic Area (Oncology, Neurology, Cardiology, Autoimmune Diseases), Discovery Phase (Biomarker Identification, Biomarker Validation,…
Biomarker and Companion Diagnostics Conference | Modeling Strategies for Biomark …
MarketsandMarkets presents the Immunobio Series, an extraordinary set of conferences taking place on 20-21 June 2024 in Boston, USA.
Register Now @ https://events.marketsandmarkets.com/2nd-annual-biomarker-and-companion-diagnostics-conference-usa-edition/register
MarketsandMarkets 5th Annual Biomarker and Companion Diagnostics Conference:
Immerse yourself in the realm of biomarkers at our flagship event, where industry leaders and experts converge to propel innovation in healthcare, diagnostics, and personalized medicine. This conference serves as a dynamic platform for collaboration, knowledge sharing, and exploration of cutting-edge…
Central Nervous System (CNS) Biomarkers Market Analysis Forecast 2023-2028 Globa …
The Central Nervous System (CNS) biomarkers market refers to the market for biomarkers used in the diagnosis, prognosis, and monitoring of diseases and disorders affecting the central nervous system. The central nervous system includes the brain and spinal cord, and disorders affecting this system can have significant impacts on an individual's health and well-being.
CNS biomarkers are measurable indicators that can provide information about the state of the central nervous system,…
Multiplex Biomarker Imaging Market - Advanced Solutions for Comprehensive Biomar …
Newark, New Castle, USA: The "Multiplex Biomarker Imaging Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiplex Biomarker Imaging Market: https://www.growthplusreports.com/report/multiplex-biomarker-imaging-market/8558
This latest report researches the industry structure,…